Porras JC, et al. - In multiple randomized controlled trials (RCTs), several systemic therapy regimens have been established as adjuvant therapy treatment options for resected pancreatic cancer, including modified FOLFRINOX (mFFX), gemcitabine and capecitabine (GemCap) and S1, mostly based on comparison with gemcitabine (Gem) alone, researchers here directly compared these regimens in RCTs and their relative survival benefits. They identified nine phase III RCTs involving 3,394 patients and 6 regimens (5-flourouracil and folinic acid, Gem, gemcitabine and erlotinib (GemErl), GemCap, mFFX and S1). Observations suggest the superiority of both mFFX and S1 to GemCap and hence these can be considered as reasonable standard treatment options for suitable patients.